Vanguard Group Inc. Acquires 59,630 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Vanguard Group Inc. increased its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,178,447 shares of the company's stock after acquiring an additional 59,630 shares during the period. Vanguard Group Inc. owned approximately 4.29% of LENZ Therapeutics worth $34,022,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of LENZ Therapeutics in the 4th quarter worth approximately $29,000. KLP Kapitalforvaltning AS bought a new stake in LENZ Therapeutics during the fourth quarter worth approximately $46,000. SG Americas Securities LLC grew its position in LENZ Therapeutics by 20.7% in the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock worth $158,000 after buying an additional 935 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of LENZ Therapeutics in the fourth quarter valued at $168,000. Finally, Raymond James Financial Inc. bought a new stake in shares of LENZ Therapeutics during the 4th quarter worth $245,000. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Trading Up 3.3 %

NASDAQ LENZ traded up $0.76 during trading on Friday, reaching $23.82. 218,555 shares of the company's stock were exchanged, compared to its average volume of 181,376. The firm has a market capitalization of $656.07 million, a PE ratio of -4.99 and a beta of 0.43. LENZ Therapeutics, Inc. has a fifty-two week low of $14.42 and a fifty-two week high of $38.93. The company's fifty day simple moving average is $23.47 and its 200-day simple moving average is $27.08.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Equities analysts forecast that LENZ Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. TD Cowen assumed coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They set a "buy" rating and a $60.00 target price on the stock. HC Wainwright restated a "buy" rating and set a $38.00 price objective on shares of LENZ Therapeutics in a report on Wednesday. Piper Sandler began coverage on shares of LENZ Therapeutics in a report on Monday. They issued an "overweight" rating and a $51.00 target price for the company. Finally, Citigroup boosted their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $46.60.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.